Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET

Company Participants

Tram Bui - Vice President, Investor Relations & Corporate Communication

Helen Torley - President & Chief Executive Officer

Nicole LaBrosse - Chief Financial Officer

Conference Call Participants

Mike DiFiore - Evercore

Corinne Jenkins - Goldman Sachs

David Risinger - SVB Securities

Jessica Fye - JPM Chase

Operator

Good afternoon. My name is Rex, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Q2 2022 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]

Thank you. At this time, I would like to introduce Tram Bui, Vice President, Investor Relations and Corporate Communication. You may begin your conference.

Tram Bui

Thank you, operator. Good afternoon and welcome to Halozyme second quarter 2022 financial and operating results conference call. In addition to our press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer, who will review our financial results for the second quarter ended June 30th, 2022.

On today's call, we will be making forward-looking statements. I refer you to our SEC filings for a risk and uncertainties. Also during the call, both GAAP and non-GAAP financial measures will be discussed. The non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.

I'll now turn the call over to Helen Torley.

Helen Torley

Thank you, Tram and good afternoon everyone. I'll begin on slide three. Our accomplishments in the first half of the year are illustrative of the many opportunities Halozyme has to continue to enhance our growth. With the acquisition of Antares, which further expanded our growth opportunities, adding a best-in-class auto-injector vector platform and a specialty commercial business, thereby augmenting Halozyme's strategy.

These additions further strengthened our position as a leading drug delivery company and expanded our strategy to include specialty products. And we continue to deliver operational excellence, achieving multiple drug delivery, commercial and corporate development milestones.